×
S&P 500   3,941.48
DOW   31,928.62
QQQ   287.24
S&P 500   3,941.48
DOW   31,928.62
QQQ   287.24
S&P 500   3,941.48
DOW   31,928.62
QQQ   287.24
S&P 500   3,941.48
DOW   31,928.62
QQQ   287.24
NYSEAMERICAN:ATNM

Actinium Pharmaceuticals (ATNM) Stock Forecast, Price & News

$5.57
-0.35 (-5.91%)
(As of 05/24/2022 12:00 AM ET)
Add
Compare
Today's Range
$5.52
$5.89
50-Day Range
N/A
52-Week Range
$4.41
$10.30
Volume
178,526 shs
Average Volume
593,434 shs
Market Capitalization
$132.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.48
30 days | 90 days | 365 days | Advanced Chart
Receive ATNM News and Ratings via Email

Sign-up to receive the latest news and ratings for Actinium Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Actinium Pharmaceuticals logo

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.

Headlines

See More Headlines

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:ATNM
CIK
N/A
Fax
N/A
Employees
32
Year Founded
N/A

Sales & Book Value

Annual Sales
$1.14 million
Book Value
$3.50 per share

Profitability

Net Income
$-22.22 million
Net Margins
-2,165.56%
Pretax Margin
-2,165.56%

Debt

Price-To-Earnings

Miscellaneous

Free Float
21,745,000
Market Cap
$132.48 million
Optionable
Optionable

Company Calendar

Last Earnings
3/30/2021
Today
5/25/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.70 out of 5 stars

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -













Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Frequently Asked Questions

Is Actinium Pharmaceuticals a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Actinium Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Actinium Pharmaceuticals stock.
View analyst ratings for Actinium Pharmaceuticals
or view top-rated stocks.

Are investors shorting Actinium Pharmaceuticals?

Actinium Pharmaceuticals saw a decline in short interest during the month of April. As of April 30th, there was short interest totaling 927,200 shares, a decline of 30.8% from the April 15th total of 1,340,000 shares. Based on an average daily volume of 818,000 shares, the short-interest ratio is presently 1.1 days.
View Actinium Pharmaceuticals' Short Interest
.

How were Actinium Pharmaceuticals' earnings last quarter?

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) released its quarterly earnings data on Tuesday, March, 30th. The biotechnology company reported ($0.37) EPS for the quarter, meeting analysts' consensus estimates of ($0.37). Actinium Pharmaceuticals had a negative net margin of 2,165.56% and a negative trailing twelve-month return on equity of 32.48%.
View Actinium Pharmaceuticals' earnings history
.

When did Actinium Pharmaceuticals' stock split? How did Actinium Pharmaceuticals' stock split work?

Shares of Actinium Pharmaceuticals reverse split before market open on Tuesday, August 11th 2020. The 1-30 reverse split was announced on Monday, August 10th 2020. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 10th 2020. An investor that had 100 shares of Actinium Pharmaceuticals stock prior to the reverse split would have 3 shares after the split.

What price target have analysts set for ATNM?

3 brokerages have issued 1 year target prices for Actinium Pharmaceuticals' shares. Their forecasts range from $25.00 to $45.00. On average, they anticipate Actinium Pharmaceuticals' stock price to reach $31.67 in the next twelve months. This suggests a possible upside of 468.5% from the stock's current price.
View analysts' price targets for Actinium Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Actinium Pharmaceuticals' key executives?
Actinium Pharmaceuticals' management team includes the following people:
  • Mr. Sandesh C. Seth M.B.A., M.S., MBA, Chairman & CEO (Age 58, Pay $1.04M)
  • Mr. Steven O'Loughlin BS, CFO & Corp. Sec. (Age 36, Pay $520k)
  • Dr. Paul Diamond Esq., Ph.D., VP of Patent & Legal Counsel
  • Dr. David Gould, Sr. VP of Corp. Devel. & Corp. Affairs
  • Dr. Bernie Cunningham, Exec. Director of Clinical Supply Chain & Logistics and CMC Project Management
  • Dr. Qing Liang, VP & Head of Radiation Sciences
  • Dr. Robert N. Daly M.S., Ph.D., VP & Head of Clinical Operations
  • Dr. Mamata Gokhale, VP & Global Head of Regulatory Affairs
  • Dr. Avinash Desai M.D., Chief Medical Officer
  • Dr. Arun Swaminathan Ph.D., Chief Bus. & Commercial Officer
What other stocks do shareholders of Actinium Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Actinium Pharmaceuticals investors own include OHR Pharmaceutical (OHRP), Fitbit (FIT), Global Ship Lease (GSL), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Gran Tierra Energy (GTE), Aeterna Zentaris (AEZS) and Bionano Genomics (BNGO).

What is Actinium Pharmaceuticals' stock symbol?

Actinium Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ATNM."

Who are Actinium Pharmaceuticals' major shareholders?

Actinium Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.88%), BlackRock Inc. (1.04%), Blair William & Co. IL (0.45%), State Street Corp (0.28%), Group One Trading L.P. (0.00%) and Simplex Trading LLC (0.00%).
View institutional ownership trends for Actinium Pharmaceuticals
.

Which institutional investors are selling Actinium Pharmaceuticals stock?

ATNM stock was sold by a variety of institutional investors in the last quarter, including ACT Capital Management LLC, and Vanguard Group Inc..
View insider buying and selling activity for Actinium Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Actinium Pharmaceuticals stock?

ATNM stock was bought by a variety of institutional investors in the last quarter, including Blair William & Co. IL, Simplex Trading LLC, Group One Trading L.P., State Street Corp, Cutler Group LP, and BlackRock Inc..
View insider buying and selling activity for Actinium Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Actinium Pharmaceuticals?

Shares of ATNM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Actinium Pharmaceuticals' stock price today?

One share of ATNM stock can currently be purchased for approximately $5.57.

How much money does Actinium Pharmaceuticals make?

Actinium Pharmaceuticals has a market capitalization of $132.48 million and generates $1.14 million in revenue each year.

How many employees does Actinium Pharmaceuticals have?

Actinium Pharmaceuticals employs 32 workers across the globe.

What is Actinium Pharmaceuticals' official website?

The official website for Actinium Pharmaceuticals is www.actiniumpharmaceuticals.com.

How can I contact Actinium Pharmaceuticals?

Actinium Pharmaceuticals' mailing address is 275 Madison Avenue, 7Th Floor, NEW YORK, NY 10016, United States. The biotechnology company can be reached via phone at (646) 677-3870 or via email at [email protected].

This page was last updated on 5/25/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.